• Cloudbreak Pharma outlined a revised funding plan for the HK$524.6 million in net IPO proceeds, shifting HK$103.6 million away from CBT-009 following the decision to withdraw its current China IND application for a possible phase 3 trial.
• Reallocated funds target faster clinical and regulatory work on CBT-001 and CBT-004, accelerated development of SFA+ pipeline assets including CBT-358 and CBT-277, and higher general corporate funding.
• Under the revised plan, total allocations rise to HK$359.2 million for CBT-001 and CBT-004 programs, HK$84.1 million for CBT-009, CBT-358 and CBT-277, HK$28.8 million for manufacturing and commercialization, and HK$52.5 million for working capital.
• CBT-358 development is being pulled forward, with a US IND submission filed on May 21, 2026, while preparations continue for FDA discussions and IND work for CBT-277.
• Unutilized proceeds stood at HK$312.6 million, with spending to be governed by tighter board-level budgeting and authorization controls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260522-12169715), on May 22, 2026, and is solely responsible for the information contained therein.